Nov. 30, 2017
Koch Biological Solutions, LLC (Koch) has secured exclusive global rights to commercialize and market products containing Asilomar Bio’s flagship yield enhancement technology for foliar, in-furrow, and other modes of application on a broad set of crops, including all major row crops and plantation forestry. The patent-pending technology represents a new class of active ingredient, which enhances crop yield potential through a novel mode-of-action.
Asilomar Bio is a privately held crop science company pioneering innovative approaches to develop technology that improves the use of crop inputs and overall yield potential. In a market with a wide spectrum of products claiming crop benefits, Asilomar’s technology is supported by rigorous field testing and a science-based development platform.
“Asilomar has developed a deep understanding of the genetic and physiological control of water and nutrient usage by plants, and we are using that knowledge as a foundation to develop products with demonstrated efficacy,” said Eric Davidson, co-founder and CEO of Asilomar Bio. “We believe Koch’s agriculture experience, commercial capabilities and shared vision of delivering scientifically validated products will provide growers with the ability to increase their yield.”
Koch has established a strong discovery platform focused on the identification, development and commercialization of products that improve plant performance. Through the proprietary discovery platform, Koch is able to enhance technologies already in the market and has developed a robust pipeline of promising candidates in various stages of development.
“We are always seeking new ways to bring customer-driven solutions to the market whether that’s through the development of our own products, or through collaborations with innovators like Asilomar,” said Bill Boycott, biologicals business leader for Koch. “We are very excited about the novel technology developed by Asilomar, and we look forward to providing science-based solutions to the problems growers face every day.”
Additional terms of the deal were not disclosed.